Key statistics dashboard for NeurAxis, Inc. (NRXS). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics.
Stock Data
| Price | $6.94 |
| Market Cap | $87M |
| Beta | 1.89 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -9.08 |
| Price / Book | 12.59 |
| P/S | 16.42 |
| P/FCF | -15.49 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 85.56% |
| EBIT Margin | -142.48% |
| EBITDA Margin | -141.10% |
| Operating Margin | -144.51% |
| Net Margin | -148.04% |
Financial Health
| Current Ratio | 3.04 |
| Quick Ratio | 2.95 |
| Cash Ratio | 2.69 |
| Debt / Equity | 0.04 |
| Debt / Assets | 2.79% |
| Interest Coverage | -148.01 |
Per-Share Data
| Revenue per share | 0.44 |
| Book Value per share | 0.56 |
| Cash per share | 0.69 |
| FCF per share | -0.46 |
| Tangible Book Value per share | 0.53 |
| Dividend per share | 0.00 |
Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRSN · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NRXS: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks